Emerging hormonal agents for the treatment of prostate cancer

References

• Huggins ML. A new society for X-ray and electron diffraction research workers. Science. 1941 May 23;93(2421):489–490.
   PubMedGoogle Scholar
• Byar DP. Proceedings: the Veterans Administration cooperative urological research group’s studies of cancer of the prostate. Cancer. 1973 Nov;32(5):1126–1130.
   PubMed Web of Science ®Google Scholar
• Khoshkar Y, Westerberg M, Adolfsson J, et al. Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort. BJUI Compass. 2022 Mar;3(2):173–183.
   PubMedGoogle Scholar
• Maluf FC, Pereira FMT, Serrano Uson PLsJr., et al. Consensus for treatment of metastatic castration-sensitive prostate cancer: report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7(7):550–558.
   PubMedGoogle Scholar
• Moreira DM, Howard LE, Sourbeer KN, et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer. 2017 Feb;15(1):60–66 e2.
   PubMed Web of Science ®Google Scholar
• Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996 Aug;14(8):2250–2257.
   PubMedGoogle Scholar
• Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. J Natl Cancer Inst. 2021 Jul 8;113(12):1648–1669.
   PubMedGoogle Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Jul 16;162(2):454.
   PubMed Web of Science ®Google Scholar
• Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003 Aug 4;89(3):552–556.
   PubMed Web of Science ®Google Scholar
• Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997 Jan 15;57(2):314–319.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate. 1996 Sep;29(3):153–158.
   PubMed Web of Science ®Google Scholar
• Taplin M-E, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25;332(21):1393–1398.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11; 371(11):1028–1038.
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008 Jul 1; 68(13):5469–5477.
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008 Jun 1;68(11):4447–4454.
   PubMed Web of Science ®Google Scholar
• Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part II: principles of active surveillance, principles of surgery, and follow-up. J Urol. 2022;10:101097JU0000000000002758.
   Google Scholar
• Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part I: introduction, risk assessment, staging and risk-based management. J Urol. 2022;10:101097JU0000000000002757.
   Google Scholar
• Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline. Part III: principles of radiation and future directions. J Urol. 2022;10:101097JU0000000000002759.
   Google Scholar
• Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497–2504.
   PubMed Web of Science ®Google Scholar
• Urbanucci A, Sahu B, Seppälä J, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene. 2012 [cited 2012 April 01];31(17):2153–2163.
   PubMed Web of Science ®Google Scholar
• Lee F, Siders DB, McHug TA, et al. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Anticancer Res. 1997 May-Jun;17(3A):1507–1510.
   PubMedGoogle Scholar
• Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006 Jun;7(6):472–479.
   PubMed Web of Science ®Google Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 4;132(7):566–577.
   PubMed Web of Science ®Google Scholar
• Waxman JH, Hendry WF, Whitfield HN, et al. A long term follow-up of patients with advanced prostatic cancer treated with buserelin. Prog Clin Biol Res. 1985;185A:271–277.
   PubMedGoogle Scholar
• Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. discussion 283-4. Eur Urol. 2004 Sep;46(3):279–283.
   PubMedGoogle Scholar
• Partin AW, Dmochowski RR, Kavoussi LR, et al. Campbell-walsh-wein urology. 12. Philadelphia: Elsevier; 2020.
   Google Scholar
• Challa AA, Calaway AC, Cullen J, et al. Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol. 2021 Apr 17;vol(6):47. 10.1007/s11864-021-00846-z.
   PubMedGoogle Scholar
• Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020 Jun 4;382(23):2187–2196.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol. 2012 Jul;19(7):594–601.
   PubMed Web of Science ®Google Scholar
• Vanuytsel L, Ang KK, Vantongelen K, et al. Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. J Urol. 1987 May;137(5):905–908.
   PubMedGoogle Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. discussion 48-53. Urology. 1996 Jan;47(1A Suppl):38–43.
   PubMedGoogle Scholar
• Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int. 2003 Mar;91(5):455–461.
   PubMedGoogle Scholar
• Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. discussion S52-4. J Urol. 2003 Dec;170(6 Pt 2):S48–52.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787–790.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016 Jun 20;34(18):2098–2106.
   PubMed Web of Science ®Google Scholar
• Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016 Feb;17(2):153–163.
   PubMed Web of Science ®Google Scholar
• Beer TM, Tombal B, Rathkopf DE. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Oct 30;371(18):1755–1756.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018 Jun 28;378(26):2465–2474.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019 Jul 11;381(2):121–131.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019 Nov 10;vol(32):2974–2986.
   PubMedGoogle Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019 Jul 4;381(1):13–24.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018 Apr 12;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019 Mar 28;380(13):1235–1246.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019 Dec 1;30(12):1992–2003.
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022 Mar 24;386(12):1132–1142.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022 Apr 30;vol(10336):1695–1707. 10.1016/S0140-6736(22)00367-1.
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Do Pazo C, Webster RM. The prostate cancer drug market. Nat Rev Drug Discov. 2021 Sep;20(9):663–664.
   PubMedGoogle Scholar
• Rathkopf DE, Scher HI. Apalutamide for the treatment of prostate cancer. Expert Rev Anticancer Ther. 2018 Sep;18(9):823–836.
   PubMed Web of Science ®Google Scholar
• Gao XsIII, Vuky J HAB, Vuky J, et al., Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022 ;40(6_suppl): 17.
   Google Scholar
• Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010 [cited 2010 June 15];17(6):535–546.
   PubMed Web of Science ®Google Scholar
• Moigne RL, Zhou H-J, Obst JK, et al. Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor. J Clin Oncol. 2019;37(7_suppl):257.
   PubMedGoogle Scholar
• Dalal K, Ban F, Li H, et al. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Cancer Lett. 2018 [cited 2018 November 28];437:35–43.
   PubMed Web of Science ®Google Scholar
• Radaeva M, Ban F, Zhang F, et al., Development of novel inhibitors targeting the D-box of the DNA binding domain of androgen receptor. Int J Mol Sci. 2021;22(5): 2493.
   PubMedGoogle Scholar
• Chen W, Mook RAsJr., Premont RT, et al. Niclosamide: beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89–96.
   PubMed Web of Science ®Google Scholar
• Parikh M, Liu C, Wu C-Y, et al. Phase Ib trial of reformulated niclosamide with Abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 [cited 2021 March 18];11(1):6377.
   PubMedGoogle Scholar
• Liu C, Armstrong CM, Lou W, et al. Niclosamide and bicalutamide combination treatment overcomes enzalutamide- and bicalutamide-resistant prostate cancer. Mol Cancer Ther. 2017;16(8):1521–1530.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Haugk K, McKiernan JS, et al. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLOS ONE. 2018;13(6):e0198389.
   PubMedGoogle Scholar
• O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015 Nov 19;60(4):547–560.
   PubMed Web of Science ®Google Scholar
• Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017 Aug 29;8(1):374.
   PubMedGoogle Scholar
• Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. PROpel: phase III trial of olaparib (ola) and Abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):11.
   Google Scholar
• Agarwal N, Azad A, Fizazi K, et al., Talapro-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2022;40(6_suppl): TPS221–TPS221.
   PubMedGoogle Scholar
• Hofman MS, Emmett L, Violet J, et al. TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603). BJU Int. 2019 Nov; 124(Suppl 1):5–13.
   PubMedGoogle Scholar
• Sartor O, de Bono J, Chi KN, et al., Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12): 1091–1103.
   PubMed Web of Science ®Google Scholar
• Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007 [cited 2007 November 01];26(52):7333–7345.
   PubMed Web of Science ®Google Scholar
• Maxwell PJ, Coulter J, Walker SM, et al. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur Urol. 2013 [cited 2013 August 01];64(2):177–188.
   PubMed Web of Science ®Google Scholar
• Aggarwal RR, Schweizer MT, Nanus DM, et al. A phase Ib/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2020;26(20):5338–5347.
   PubMedGoogle Scholar